The University of Southampton
University of Southampton Institutional Repository

Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia

Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia
Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia

Between June 1994 and October 1995 we performed 11 autografts in nine patients with advanced-phase chronic myeloid leukaemia (CML) using an attenuated cytoreductive regimen consisting of busulphan 8 mg/kg given in divided doses over 4 d. Five patients were restored to chronic phase. Four patients survived > 50 weeks and one remains well at 79 weeks. Toxicity was generally mild. Four procedures were managed entirely in the out-patient clinic. Therefore autografting after this 'intermediate' dose busulphan provides good palliation for patients with advanced CML with relatively little toxicity. Attenuated autografting should offer major advantages in terms of quality of life and cost for patients with advanced-phase CML.

Adult, Aged, Bone Marrow Transplantation, Busulfan, Female, Graft Survival, Hematopoietic Stem Cell Transplantation, Hospitalization, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Neutrophils, Recurrence, Transplantation, Autologous, Journal Article, Research Support, Non-U.S. Gov't
0007-1048
694-8
Rule, S A
81970997-971e-4613-adf5-69a6a627819c
Savage, D G
d5c881f3-6f16-4d80-9642-e5267fb6078d
O'Brien, S G
a85a52b4-607a-4210-9d41-11f2b4e46476
Orchard, K
794654ab-d6cc-488a-ac11-c9217433c7a2
McDonald, C
fd9f9d68-ad7a-4e82-a88d-a2dbc623ce91
Davidson, J
6e7db175-3f74-4054-96ae-bcad692bd7c7
Matthey, F
4cbac402-abaa-4ebb-932a-66ec0d6a992f
Reilly, J T
e59749f5-75e2-46a2-95b5-a3fce8742b32
Bardhan, G
fe3a83f1-4896-4804-a106-07c27211f482
Miller, E
7f0dfd3d-6200-4467-b4c0-f208e9004c8a
Cranfield, T
91edc1c4-8fba-4f9b-a42b-fd14b6e9fd84
Apperley, J F
f328fa9a-e8b6-4744-8bcf-ec74abc5ddc1
Goldman, J M
2c27a1b3-c445-4593-a6b5-2e6e749fa1cb
Rule, S A
81970997-971e-4613-adf5-69a6a627819c
Savage, D G
d5c881f3-6f16-4d80-9642-e5267fb6078d
O'Brien, S G
a85a52b4-607a-4210-9d41-11f2b4e46476
Orchard, K
794654ab-d6cc-488a-ac11-c9217433c7a2
McDonald, C
fd9f9d68-ad7a-4e82-a88d-a2dbc623ce91
Davidson, J
6e7db175-3f74-4054-96ae-bcad692bd7c7
Matthey, F
4cbac402-abaa-4ebb-932a-66ec0d6a992f
Reilly, J T
e59749f5-75e2-46a2-95b5-a3fce8742b32
Bardhan, G
fe3a83f1-4896-4804-a106-07c27211f482
Miller, E
7f0dfd3d-6200-4467-b4c0-f208e9004c8a
Cranfield, T
91edc1c4-8fba-4f9b-a42b-fd14b6e9fd84
Apperley, J F
f328fa9a-e8b6-4744-8bcf-ec74abc5ddc1
Goldman, J M
2c27a1b3-c445-4593-a6b5-2e6e749fa1cb

Rule, S A, Savage, D G, O'Brien, S G, Orchard, K, McDonald, C, Davidson, J, Matthey, F, Reilly, J T, Bardhan, G, Miller, E, Cranfield, T, Apperley, J F and Goldman, J M (1996) Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia. British Journal of Haematology, 94 (4), 694-8.

Record type: Article

Abstract

Between June 1994 and October 1995 we performed 11 autografts in nine patients with advanced-phase chronic myeloid leukaemia (CML) using an attenuated cytoreductive regimen consisting of busulphan 8 mg/kg given in divided doses over 4 d. Five patients were restored to chronic phase. Four patients survived > 50 weeks and one remains well at 79 weeks. Toxicity was generally mild. Four procedures were managed entirely in the out-patient clinic. Therefore autografting after this 'intermediate' dose busulphan provides good palliation for patients with advanced CML with relatively little toxicity. Attenuated autografting should offer major advantages in terms of quality of life and cost for patients with advanced-phase CML.

Full text not available from this repository.

More information

Published date: September 1996
Keywords: Adult, Aged, Bone Marrow Transplantation, Busulfan, Female, Graft Survival, Hematopoietic Stem Cell Transplantation, Hospitalization, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Neutrophils, Recurrence, Transplantation, Autologous, Journal Article, Research Support, Non-U.S. Gov't
Organisations: Cancer Sciences, Transactions & Procurement, Humanities: Central Faculty

Identifiers

Local EPrints ID: 411597
URI: https://eprints.soton.ac.uk/id/eprint/411597
ISSN: 0007-1048
PURE UUID: e0933afb-daca-4e8d-96bd-a331b9be5b91
ORCID for K Orchard: ORCID iD orcid.org/0000-0003-2276-3925

Catalogue record

Date deposited: 21 Jun 2017 16:31
Last modified: 12 Nov 2019 01:50

Export record

Contributors

Author: S A Rule
Author: D G Savage
Author: S G O'Brien
Author: K Orchard ORCID iD
Author: C McDonald
Author: J Davidson
Author: F Matthey
Author: J T Reilly
Author: G Bardhan
Author: E Miller
Author: T Cranfield
Author: J F Apperley
Author: J M Goldman

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×